Department of Laboratory Medicine, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhengzhou Key Laboratory for In Vitro Diagnosis of Hypertensive Disorders of Pregnancy, Zhengzhou, China.
Sci Rep. 2024 Nov 16;14(1):28295. doi: 10.1038/s41598-024-77153-8.
Cardiac biomarkers are being increasingly applied in pediatric populations, including those with cardiogenic and non-cardiogenic myocardial injury disease. The upper reference limits of biomarkers are an important reference for disease diagnosis and health evaluation. However, the upper reference limits of pediatric cardiac biomarkers remains unknown. A total of 1,797 serum samples were collected prospectively from healthy respondents aged 0 to 18 years old. These samples were analyzed using Roche cobas e411 to determine the concentrations of hs-cTnT, CK-MB mass, and NT-proBNP. The upper reference limits and 90% confidence interval were calculated according to Clinical and Laboratory Standards Institute C28- A3 guidelines. The study successfully established the upper reference limits for hs-cTnT, CK-MB mass, and NT-proBNP in healthy children and adolescents aged 0 to 18. The hs-cTnT, CK-MB mass, and NT-proBNP levels were visibly higher in neonatal serum. With the increase in age, hs-cTnT, CK-MB mass, and NT-proBNP decline gradually. They decrease quickly in the first year after birth and decrease slowly after 1 year old. Gender differences were observed in the concentrations of hs-cTnT and CK-MB mass among healthy children and teenagers aged 10 to 18 and 13 to 18. Specifically, boys had relatively higher concentrations of hs-cTnT and CK-MB mass. However, no gender difference was found in NT-proBNP concentration. The concentrations of hs-cTnT, CK-MB mass, and NT-proBNP were simultaneously tested in healthy Chinese children for the first time. The specific upper reference limits of age and gender in pediatrics were established. The results provide comprehensive references for medical institutions specializing in children's healthcare, which are conducive to preliminary screening, diagnosis, and treatment of pediatric cardiovascular diseases.
心脏生物标志物在儿科人群中的应用越来越广泛,包括患有心源和非心源心肌损伤疾病的人群。生物标志物的上限参考值是疾病诊断和健康评估的重要参考。然而,儿科心脏生物标志物的上限参考值仍不清楚。前瞻性收集了 1797 份 0 至 18 岁健康应答者的血清样本。使用罗氏 cobas e411 分析这些样本,以确定 hs-cTnT、CK-MB 质量和 NT-proBNP 的浓度。根据临床和实验室标准协会 C28-A3 指南计算上限参考值和 90%置信区间。该研究成功建立了 0 至 18 岁健康儿童和青少年 hs-cTnT、CK-MB 质量和 NT-proBNP 的上限参考值。新生儿血清中的 hs-cTnT、CK-MB 质量和 NT-proBNP 水平明显较高。随着年龄的增长,hs-cTnT、CK-MB 质量和 NT-proBNP 逐渐下降。出生后第一年下降较快,1 岁后下降较慢。在 10 至 18 岁和 13 至 18 岁的健康儿童和青少年中,hs-cTnT 和 CK-MB 质量的浓度存在性别差异。具体而言,男孩的 hs-cTnT 和 CK-MB 质量浓度相对较高。然而,NT-proBNP 浓度没有性别差异。首次在健康中国儿童中同时检测 hs-cTnT、CK-MB 质量和 NT-proBNP。建立了儿科特定的年龄和性别上限参考值。这些结果为专门从事儿童保健的医疗机构提供了全面的参考,有利于儿童心血管疾病的初步筛查、诊断和治疗。